Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 4/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18741586 | 1.00 | GSR (0.50) | GSROTCNOS2NOS3NOS1 | |
| SCHEMBL8709636 | 1.00 | GSR (0.50) | GSROTCNOS2NOS3NOS1 | |
| SCHEMBL3727819 | 0.94 | GSR (0.53) | GSROTCNOS2NOS3NOS1 | |
| SCHEMBL1932144 | 0.94 | GSR (0.53) | GSROTCNOS2NOS3NOS1 | |
| SCHEMBL457067 | 0.94 | GSR (0.53) | GSROTCNOS2NOS3NOS1 | |
| SCHEMBL25406097 | 0.88 | SLC1A3 (0.46) | GSRKMT2ACYP1A2SLC7A5GRM8 | |
| SCHEMBL2236943 | 0.88 | SLC1A3 (0.46) | GSRKMT2ACYP1A2SLC7A5GRM8 | |
| SCHEMBL2236935 | 0.88 | SLC1A3 (0.46) | GSRKMT2ACYP1A2SLC7A5GRM8 | |
| Hydrochloric Acid SCHEMBL29176246 | 0.86 | GSR (0.48) | GSROTCNOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL30839685 | 0.86 | GSR (0.48) | GSROTCNOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068346-A1 | PHARMACEUTICAL COMBINATION OF CXCR4, PD-1 AND FAK INHIBITORS FOR TREATING CANCER | SPEXIS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| WO-2025068348-A1 | PHARMACEUTICAL COMBINATION OF CXCR4 AND PD-1 INHIBITORS FOR TREATING CANCER | SPEXIS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | claimed |
| US-20240228555-A9 | ANTIMICROBIAL PEPTIDOMIMETICS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-07-11 | — | — | US | claimed |
| EP-4380689-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Basilea Pharmaceutica International AG, Allschwil (CH) | 2024-06-12 | — | — | EP | claimed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | claimed |
| US-20240132553-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2024-04-25 | — | — | US | claimed |
| US-11883501-B2 | Selective CXCR4 binding peptide conjugate and methods for making and using the same | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2024-01-30 | — | — | US | claimed |
| US-20240009266-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER | SPEXIS AG (CH) | 2024-01-11 | — | — | US | claimed |
| US-11771736-B2 | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2023-10-03 | — | — | US | claimed |
| EP-4214220-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | claimed |
| CN-115989236-A | Antimicrobial peptidomimetics | 斯派西斯公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | claimed |
| WO-2023285677-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | claimed |
| WO-2023285681-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | claimed |
| EP-4097120-A1 | ISOTOPICALLY LABELLED SELECTIVE CXCR4 BINDING PEPTIDE CONJUGATE AND METHODS FOR MAKING AND USING THE SAME | Mainline Biosciences LLC (US) | 2022-12-07 | — | — | EP | claimed |
| WO-2022184320-A2 | MEDICAL USE OF CYCLIC PEPTIDES | SPEXIS AG (CH) | 2022-09-09 | — | — | WO | claimed |
| WO-2022106061-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER | POLYPHOR AG (CH) | 2022-05-27 | — | — | WO | claimed |
| EP-4000613-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER | Polyphor Ag (CH) | 2022-05-25 | — | — | EP | claimed |
| WO-2022028737-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883501-B2 | Selective CXCR4 binding peptide conjugate and methods for making and using the same | CXCR4, CXCR1, ACKR3 | GSR 4865/4885OTC 4860/4885NOS2 4371/4885 |
| US-11771736-B2 | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same | CXCR4, CXCR3, CXCR1 | GSR 4169/4885OTC 4675/4885NOS2 4065/4885 |
| US-20240009266-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER | CXCR4, CXCL12, CXCR1 | GSR 4449/4885OTC 4696/4885NOS2 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.